IMBiotechnologies said last week it treated the 1st patient in a clinical trial of its biodegradable OCL500 embolization microspheres to treat uterine fibroids. The OCL500 microspheres are designed to rapidly form site-specific, platelet-rich clots that cut off the blood supply to target tissues and completely biodegrade over time, Canada-based IMBiotechnologies said. “We are pleased to announce […]